Cancer of the nasal cavity in the pediatric population

被引:35
作者
Benoit, Margo McKenna [1 ,2 ]
Bhattacharyya, Neil [2 ,3 ]
Faquin, William [4 ]
Cunningham, Michael [1 ,2 ]
机构
[1] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA USA
[3] Brigham & Womens Hosp, Div Otolaryngol, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
关键词
esthesioneuroblastoma; rhabdomyosarcoma; nasal obstruction; neoplasm; CRANIOFACIAL RESECTION; ESTHESIONEUROBLASTOMA; PROGNOSIS; SURVIVAL; SARCOMA; RHABDOMYOSARCOMA; RADIOTHERAPY; CHILDHOOD; TUMORS; SINUS;
D O I
10.1542/peds.2007-1319
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE. The purpose of this work was to investigate the clinical manifestations and diagnostic range of malignant entities presenting as a nasal mass in the pediatric population. PATIENTS AND METHODS. A retrospective cohort analysis was conducted at a specialty hospital and a tertiary care university hospital. Patients aged between birth and 18 years and diagnosed with a malignancy that arose within the nasal cavity between the years 1991 and 2006 were included. This institution-specific patient group was compared with a similar cohort of patients extracted from the national Surveillance Epidemiology and End Results database. The main outcome measures were the incidence, presentation, and diagnoses of nasal cancer presenting in this population. RESULTS. Sixteen patients with nasal malignancies presented institutionally in the defined pediatric age group. Patient age at the time of diagnosis ranged from 7 months to 17 years, with a slight male predominance. The main presenting symptoms were unilateral nasal congestion and ophthalmologic complaints. The median time from presentation to diagnosis was 7 weeks; patients who presented with nonspecific complaints, such as nasal obstruction, headache, and fatigue, were given a diagnosis, on average, later than those who presented with focal manifestations. Nationwide, 47 patients were identified from the Surveillance Epidemiology and End Results database. In both subject groups, the most common diagnoses were rhabdomyosarcoma (37.5% institutionally and 23% in the Surveillance Epidemiology and End Results group) and esthesioneuroblastoma (25% institutionally and 28% Surveillance Epidemiology and End Results). In the Surveillance Epidemiology and End Results cohort, the overall mean survival rate was 188 months. CONCLUSIONS. Nasal cancer in the pediatric population often presents with nonspecific signs and symptoms, and a high index of suspicion is necessary for a timely diagnosis. Soft tissue sarcomas are expectedly common. The relative high frequency of esthesioneuroblastoma is particularly noteworthy.
引用
收藏
页码:E141 / E145
页数:5
相关论文
共 28 条
  • [1] Barnes EL., 2005, World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours
  • [2] Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the childhood cancer survivor study
    Bassal, M
    Mertens, AC
    Taylor, L
    Neglia, JP
    Greffe, BS
    Hammond, S
    Ronckers, CM
    Friedman, DL
    Stovall, M
    Yasui, YY
    Robison, LL
    Meadows, AT
    Kadan-Lottick, NS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 476 - 483
  • [3] BENTZ B, 2003, HEAD NECK-J SCI SPEC, P515
  • [4] Cancer of the nasal cavity - Survival and factors influencing prognosis
    Bhattacharyya, N
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2002, 128 (09) : 1079 - 1083
  • [5] BILLER HF, 1990, LARYNGOSCOPE, V100, P1199
  • [6] BULSARA K, 2002, NEUROSURG FOCUS, V13, P1
  • [7] Esthesioneuroblastoma: a meta-analysis and review
    Dulguerov, P
    Allal, AS
    Calcaterra, TC
    [J]. LANCET ONCOLOGY, 2001, 2 (11) : 683 - 690
  • [8] Dulguerov Pavel, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P67
  • [9] Eich HT, 2005, STRAHLENTHER ONKOL, V181, P378, DOI 10.1007/s00066-005-1362-2
  • [10] Eich HT, 2003, STRAHLENTHER ONKOL, V179, P233, DOI 10.1007/s00066-003-1089-x